Ergomar

Vascular Headaches, Postpartum state, Cluster Headache + 2 more

Treatment

4 FDA approvals

20 Active Studies for Ergomar

What is Ergomar

Ergotamine

The Generic name of this drug

Treatment Summary

Ergotamine is a drug found in ergot, a fungus that grows on rye grain. It is used to treat migraine headaches by narrowing the blood vessels. Ergotamine is classified as an alpha-1 selective adrenergic agonist and works by stimulating certain receptors in the body.

Cafergot

is the brand name

image of different drug pills on a surface

Ergomar Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cafergot

Ergotamine

1953

15

Approved as Treatment by the FDA

Ergotamine, also known as Cafergot, is approved by the FDA for 4 uses which include Migraine and Cluster Headache .

Migraine

Cluster Headache

Vascular Headaches

Used to treat Vascular Headaches in combination with Caffeine

Neuralgia

Effectiveness

How Ergomar Affects Patients

Ergotamine is a drug that affects multiple systems in the body. It constricts peripheral and cranial blood vessels, influences the activity of tryptaminergic, dopaminergic, and alpha adrenergic receptors, and can stimulate the uterus. It is thought to help with migraine pain by decreasing the pulsations in the cranial arteries and reducing blood flow in the extracranial area. It does not, however, affect cerebral hemispheric blood flow.

How Ergomar works in the body

Ergotamine works to stop migraines by constricting blood vessels in the head and blocking the release of pro-inflammatory chemicals from nerves in the trigeminal system. This is done by stimulating 5-HT1D receptors, which are located on both blood vessels and nerve endings.

When to interrupt dosage

The recommended dose of Ergomar is contingent upon the acknowledged condition, like Postpartum state, Cluster Headache and Uterine Atony. The magnitude of dosage varies as indicated by the mode of delivery noted in the table beneath.

Condition

Dosage

Administration

Migraine

1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet - Oral, Tablet, Rectal, Suppository, Suppository - Rectal, Tablet, orally disintegrating, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol - Oral, Aerosol

Vascular Headaches

1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet - Oral, Tablet, Rectal, Suppository, Suppository - Rectal, Tablet, orally disintegrating, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol - Oral, Aerosol

Cluster Headache

1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet - Oral, Tablet, Rectal, Suppository, Suppository - Rectal, Tablet, orally disintegrating, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol - Oral, Aerosol

Postpartum state

1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet - Oral, Tablet, Rectal, Suppository, Suppository - Rectal, Tablet, orally disintegrating, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol - Oral, Aerosol

Uterine Inertia

1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet - Oral, Tablet, Rectal, Suppository, Suppository - Rectal, Tablet, orally disintegrating, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol - Oral, Aerosol

Warnings

Ergomar Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Renal Insufficiency

Do Not Combine

Coronary Heart Disease

Do Not Combine

Peripheral Vascular Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ergomar.

Common Ergomar Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Ergotamine.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Ergotamine.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Ergotamine.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ergotamine.

4-Bromo-2,5-dimethoxyphenethylamine

Major

Ergotamine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine.

Ergomar Toxicity & Overdose Risk

Signs of an overdose on a drug may include irritation, nausea, vomiting, headache, diarrhea, increased thirst, cold skin, itching, weak heartbeat, numbness and tingling in the limbs, and confusion.

image of a doctor in a lab doing drug, clinical research

Ergomar Novel Uses: Which Conditions Have a Clinical Trial Featuring Ergomar?

69 active clinical trials are currently being conducted to assess the potential of Ergomar to alleviate Migraine, Uterine Atony and Postpartum state disorders.

Condition

Clinical Trials

Trial Phases

Vascular Headaches

0 Actively Recruiting

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Postpartum state

11 Actively Recruiting

Not Applicable, Phase 4, Phase 1

Uterine Inertia

1 Actively Recruiting

Phase 2

Cluster Headache

2 Actively Recruiting

Phase 1, Phase 2

Ergomar Reviews: What are patients saying about Ergomar?

5

Patient Review

4/3/2012

Ergomar for Migraine Headache

This medication always abort my migraines, and I'm so thankful for that!

5

Patient Review

2/1/2008

Ergomar for Migraine Headache

4.7

Patient Review

2/6/2008

Ergomar for Migraine Headache

I'm using this medication for the first time tonight in hopes that it will help to reduce my migraines and vomiting. So far, I don't have much to go off of.

4.3

Patient Review

6/12/2011

Ergomar for Migraine Headache

This medication quickly and effectively relieved my migraine pain.

3.7

Patient Review

1/6/2008

Ergomar for Migraine Headache

3.7

Patient Review

1/6/2008

Ergomar for Migraine Headache

3

Patient Review

2/19/2008

Ergomar for Migraine Headache

Ergomar has been working well for me for a long time. I appreciate that it has a gentle onset and that I don't need water to take it.

2.3

Patient Review

6/6/2021

Ergomar for Migraine Headache

Unfortunately, this pill did not help with my migraines. On the contrary, it made me feel worse by causing heart and breathing problems. I will not be taking any more of this medication.

1

Patient Review

7/29/2011

Ergomar for Migraine Headache

I'm not a fan of this treatment
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ergomar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What ergotamine is used for?

"Dihydroergotamine and ergotamine areReduce the size of blood vessels and relieve the pain of throbbing headaches, such as migraine and cluster headaches. Dihydroergotamine and ergotamine are not painkillers that will relieve any other type of pain."

Answered by AI

What is Ergomar used for?

"Ergomar is an ergot alkaloid used to treat a migraine type headache that has already begun, but will not prevent migraine headaches or reduce the number of attacks."

Answered by AI

What is the drug Cafergot used for?

"This drug is a combination of two medications, ergotamine and caffeine, which are used to relieve pain from migraines and cluster headaches. The ergotamine works by constricting the blood vessels in the head, which alleviates the pain."

Answered by AI

Is Ergomar a triptan?

"Ergomar and triptan medications like Imitrex and Maxalt have similar mechanism of action and side effects. Simultaneous use of these medications can lead to increased blood pressure and other serious side effects."

Answered by AI

Clinical Trials for Ergomar

Image of Children's Mercy in Kansas City, United States.

Virtual Reality Neurofeedback for Migraine

10 - 16
All Sexes
Kansas City, MO

The goal of this clinical trial is to learn whether a home-based virtual reality (VR) neurofeedback program is feasible and acceptable for adolescents with migraine. The study will also explore whether the program may improve headache-related outcomes. The main questions it aims to answer are: Is it feasible to enroll, randomize, and retain adolescents with migraine in this study? Do participants complete the VR sessions and study procedures as intended? Are there preliminary signals that the VR neurofeedback program may improve headache-related disability and symptoms? Researchers will compare Immersive Neurofeedback Self-Regulation Training (INSeRT), which uses brain activity recorded from a wearable electroencephalogram (EEG) headband to guide the VR experience, to a comparison VR program that presents immersive imagery without neurofeedback or guided relaxation training. Participants will: Complete a 4-week baseline period that includes headache logs, questionnaires, and a laboratory EEG assessment Be randomly assigned to one of two VR programs Complete VR sessions at home three times per week for 4 weeks Complete questionnaires at the end of treatment and again approximately 3 months later Repeat the laboratory EEG assessment at the end of treatment

Recruiting
Has No Placebo

Children's Mercy

Mark A Connelly, PhD

Have you considered Ergomar clinical trials?

We made a collection of clinical trials featuring Ergomar, we think they might fit your search criteria.
Go to Trials
Image of University of British Columbia in Vancouver, Canada.

STORK Program for Postpartum Well-Being

18+
All Sexes
Vancouver, Canada

Becoming parents exerts powerful and long-lasting effects on couples' well-being and quality of life. The transition to parenthood (TtP; pregnancy to 12-months postpartum) poses significant challenges as couples balance the task of caring for a newborn while maintaining their romantic relationship. One crucial way that couples sustain their connection is through their sexuality. Most new parents experience significant disruptions to their sexual well-being (i.e., sexual satisfaction, desire, distress), with sexual concerns such as reduced sexual frequency and lack of time and energy for sex being nearly ubiquitous. Simultaneously, most new parents lack easily accessible, reliable information on the common sexual changes associated with the TtP and there is a lack of evidence-based research aimed at helping couples navigate changes to their sexual well-being across this life transition. The investigators have identified risk (e.g., stress) and protective (e.g., intimacy) factors for couples' sexual well-being across the TtP that can be targeted in a prevention program, though no such programs exist. The goal of this two-centre randomized controlled trial is to evaluate the efficacy of STORK (Supporting the Transition to Parenthood through Online Sex and Relationship Knowledge), a novel couple-based online program to support new parents' sexual well-being. This program comprises psychoeducation about common sexual changes as well as skills that couples can develop together to manage these changes and constitutes the first evidence-based program for new parent couples' sexual well-being. The investigators expect that, compared to a waitlist control group, couples who complete STORK will have better sexual, relational, and psychological adjustment across the transition to parenthood (from 13 to 27-weeks gestation to 12-months postpartum). Given that up to 78% of new parents report receiving little-to-no information about what to expect regarding changes to their postpartum sexual relationship, this study addresses the need for accessible, couple-based supports for this commonly challenging transition. By strengthening couples' sexual relationships, the results of this research have the potential to promote the quality of new parents' relationships, strengthening the overall well-being of their families during this critical life stage.

Waitlist Available
Has No Placebo

University of British Columbia (+1 Sites)

Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Have you considered Ergomar clinical trials?

We made a collection of clinical trials featuring Ergomar, we think they might fit your search criteria.
Go to Trials
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD

This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.

Recruiting
Has No Placebo

Johns Hopkins Medicine

Risheng Xu, MD, PhD

Medtronic

Image of University of Maryland in Baltimore, United States.

Contingency Management for Substance Use During Pregnancy

18+
Female
Baltimore, MD

Substance use during pregnancy is a leading cause of maternal morbidity and mortality in the United States, with 55-80% of postpartum patients disengaging from substance use disorder (SUD) treatment within one year of delivery. Structural and social determinants of health, including housing instability, transportation barriers, and limited childcare access, further exacerbate disparities in treatment retention. This pilot study, conducted in two specialized prenatal care clinics, evaluates the feasibility and acceptability of two integrated strategies to promote sustained engagement in recovery-oriented services during the perinatal and postpartum periods. Aim 1 implements a standardized social needs screening and referral protocol to connect patients with community-based supports. Aim 2 pilots a contingency management intervention to incentivize recovery-supportive behaviors. Findings will inform the design of a larger multi-site randomized controlled trial to evaluate the impact of these interventions on treatment retention, overdose prevention, and maternal-infant health outcomes.

Recruiting
Has No Placebo

University of Maryland (+1 Sites)

Ana Baumann Walker, PhD, MA

Have you considered Ergomar clinical trials?

We made a collection of clinical trials featuring Ergomar, we think they might fit your search criteria.
Go to Trials